Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Melanin’s Ability to Maintain Radioprotection Examined

By BiotechDaily International staff writers
Posted on 07 Sep 2011
Print article
Sun worshipers have long known that melanin in their skin cells provides protection from the damage caused by visible and ultraviolet light. More recent studies have shown that melanin, which is produced by multitudes of organisms, also provides some species with protection from ionizing radiation.

In certain microbes, in particular some organisms from near the former nuclear reactor facilities in Chernobyl (Ukraine), melanin has even been linked to increased growth in the presence of ionizing radiation.

Research at the US Department of Energy’s Savannah River National Laboratory (SRNL; Aiken, SC, USA), in collaboration with the Albert Einstein College of Medicine (Bronx, NY, USA), has provided clues into the electrochemical mechanism that gives the complex polymer known as melanin its long-term radioprotective properties, with an objective of using that knowledge to develop materials that mimic those natural properties.

An article in the August 2011 issue of the journal Bioelectrochemistry described how the researchers established that ionizing radiation interacts with melanin to alter its oxidation-reduction potential, resulting in electric current production.

Radiation causes damage by stripping away electrons from its target. “Over time, as melanin is bombarded with radiation and electrons are knocked away, you would expect to see the melanin become oxidized, or bleached out, and lose its ability to provide protection,” said Dr. Charles Turick, science fellow with SRNL, “but that’s not what we’re seeing. Instead, the melanin continuously restores itself.”

The investigator’s research took them a step closer to clarifying that self-restoration process. They demonstrated that melanin could receive electrons, countering the oxidizing effects of the gamma radiation. The work showed, for the first time, that constant exposure of melanin to gamma radiation results in electric current production.

Mimicking that capability would be beneficial, for example, in the space industry, where satellites and other equipment are exposed to high levels of radiation for long spans of time. “Looking at materials, a constantly gamma radiation-oxidized electrode consisting in part of melanin would continuously accept electrons, thereby resulting in a current response,” Dr. Turick said. “If we could understand how that works, we could keep that equipment working for a very long time.”


Related Links:
Energy’s Savannah River National Laboratory
Albert Einstein College of Medicine





Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.